{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:15:18Z","timestamp":1776057318954,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPGN rep."],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Objectives:<\/jats:title><jats:p>Autoimmune hepatitis (AIH) can lead to progressive fibrosis in patients refractory to conventional therapy with prednisolone and azathioprine. The use of mammalian target of rapamycin (mTOR) inhibitors has recently emerged in refractory AIH, but no data have been published about everolimus in pediatric AIH to date. Our aim was to share our experience about everolimus as a second\u2010\/third\u2010line therapy in pediatric AIH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>Pretransplant AIH patients aged 0\u201318 years who received everolimus therapy from 2014 to 2021 were retrospectively identified. All patients underwent regular plasma monitoring of everolimus trough levels to avoid toxicity and assess adherence. Special attention was paid to the clinical and biochemical occurrence of everolimus\u2010related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>We report six difficult\u2010to\u2010treat AIH patients who received everolimus therapy for 8\u201346 months (median 28 months). No side effects were reported when everolimus plasma trough levels were in the therapeutic range. Liver transaminases improved in 5 of 6 patients at everolimus introduction and significantly decreased at the last follow\u2010up (FU) in our cohort (<jats:italic>P<\/jats:italic> &lt; 0.05). None of our patients achieved complete biochemical remission at the last FU and 3 of 6 admitted to have suboptimal adherence to therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Our data bring preliminary safety for the use of everolimus as a second\u2010\/third\u2010line therapy in pediatric AIH. Although liver transaminases improved in our cohort, prospective studies are needed to determine if everolimus can induce long\u2010term remission.<\/jats:p><\/jats:sec>","DOI":"10.1097\/pg9.0000000000000227","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T18:00:09Z","timestamp":1660672809000},"source":"Crossref","is-referenced-by-count":4,"title":["Everolimus is Safe as a Second\u2010\/Third\u2010Line Therapy in Pediatric Autoimmune Hepatitis"],"prefix":"10.1002","volume":"3","author":[{"given":"Giulia","family":"Jannone","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pediatric Gastroenterology and Hepatology Unit Cliniques Universitaires Saint\u2010Luc, Universit\u00e9 Catholique de Louvain Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Scheers","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Gastroenterology and Hepatology Unit Cliniques Universitaires Saint\u2010Luc, Universit\u00e9 Catholique de Louvain Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Smets","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Gastroenterology and Hepatology Unit Cliniques Universitaires Saint\u2010Luc, Universit\u00e9 Catholique de Louvain Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Stephenne","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Gastroenterology and Hepatology Unit Cliniques Universitaires Saint\u2010Luc, Universit\u00e9 Catholique de Louvain Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"M Sokal","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Gastroenterology and Hepatology Unit Cliniques Universitaires Saint\u2010Luc, Universit\u00e9 Catholique de Louvain Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001801"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199510123331502"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31065"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i33.6030"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.17"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23792"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/jlts.2001.24645"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3932"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002495"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2546"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.1040388"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.06.016"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-015-4022-0"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318291feaa"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3109\/00365521.2014.998271"},{"key":"e_1_2_7_17_1","doi-asserted-by":"crossref","unstructured":"GanschowR EriczonBG DhawanA et al. Everolimus and reduced calcineurin inhibitor therapy in pediatric liver transplant recipients: results from a multicenter prospective study.Pediatr Transplant.2017;21.","DOI":"10.1111\/petr.13024"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3046.2011.01515.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2018.11.010"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000239735.87111.ba"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23584"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.22131"},{"key":"e_1_2_7_23_1","first-page":"1006","article-title":"Fibrosis and inflammation histology scores predict disease remission in pediatric autoimmune hepatitis","volume":"2","author":"Jannone G","year":"2017","journal-title":"JSM Hepatitis"}],"container-title":["JPGN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1097\/PG9.0000000000000227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T14:51:32Z","timestamp":1749739892000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1097\/PG9.0000000000000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1097\/PG9.0000000000000227"],"URL":"https:\/\/doi.org\/10.1097\/pg9.0000000000000227","archive":["Portico"],"relation":{},"ISSN":["2691-171X","2691-171X"],"issn-type":[{"value":"2691-171X","type":"print"},{"value":"2691-171X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"article-number":"e227"}}